ArticleSchizophrenia bulletin open2026
Aerobic Exercise for Cognitive and Functional Enhancement in Schizophrenia: Evidence, Mechanisms, and Practical Recommendations.
Article in Schizophrenia bulletin open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a psychiatric condition often characterized by cognitive deficits which precede the onset of positive symptoms and contribute significantly to enduring functional impairments and poor quality of life. Those cognitive deficits can have a profoundly negative impact on daily activities such as social relationships and work functioning. Although pharmacological interventions remain central to the treatment of schizophrenia (SZ), they have a negligible impact on cognitive functioning. Yet multiple reviews and meta-analyses support the hypothesis that Aerobic Exercise (AE) could serve as an adjunctive, therapeutic intervention for these cognitive impairments. AE is recommended for individuals with Multi-episode Psychosis (MEP) and with First Episode Psychosis (FEP). This body of evidence indicates that for individuals with SZ, engagement in AE shows measurable enhancements in specific brain regions associated with key domains of neurocognitive functioning. AE has also been associated with improvements in neurobiological processes including increased BDNF, enhanced neurogenesis, and improved neural connectivity. These improvements were linked to key cognitive domains associated daily functioning such as attention, working memory, reasoning, speed of processing, and social cognition. Engagement in AE has also been associated with improvements in Activities of Daily Living, reductions in psychiatric symptoms, improvements in psychosocial functioning, and good quality of life. Endorsements and specific guidelines have been published worldwide from leading governmental health agencies and international professional psychiatric organizations. These recommendations have been summarized so that practitioners can implement AE programs for individuals with SZ using group and/or individually tailored interventions to boost motivation and enhance self-efficacy for engaging in AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.